N@N

Paul Matteis Maintained (ACAD) at Hold with Increased Target to $27 on, Dec 18th, 2023

Paul Matteis of Stifel, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Increased Target from $25 to $27 on, Dec 18th, 2023.

Paul has made no other calls on ACAD in the last 4 months.

There are 11 other peers that have a rating on ACAD. Out of the 11 peers that are also analyzing ACAD, 2 agree with Paul's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Neena Bitritto-Garg of "Deutsche Bank" Downgraded from Strong Buy to Hold and Held Target at $25 on, Thursday, December 14th, 2023
• Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $31 on, Friday, November 3rd, 2023

These are the ratings of the 9 analyists that currently disagree with Paul

---

• Charles Duncan of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $42 on, Thursday, December 14th, 2023
• David Hoang of "Citigroup" Initiated at Strong Buy and Held Target at $38 on, Wednesday, December 13th, 2023
• Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $40 on, Monday, November 6th, 2023
• Uy Ear of "Mizuho" Upgraded from Hold to Strong Buy and Increased Target to $35 on, Monday, November 6th, 2023
• Gregory Renza of "RBC Capital" Maintained at Buy with Increased Target to $33 on, Friday, November 3rd, 2023
• Jason Butler of "JMP Securities" Maintained at Buy with Increased Target to $42 on, Friday, November 3rd, 2023
• Ashwani Verma of "UBS" Initiated at Strong Buy and Held Target at $33 on, Tuesday, October 17th, 2023
• Tessa Romero of "JP Morgan" Upgraded from Hold to Buy and Increased Target to $32 on, Tuesday, October 10th, 2023
• Sarah James of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $42 on, Tuesday, August 22nd, 2023

Contributing Sources

---